The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Open accessAbstract
After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” lesions, disorders with limited capacity for clinical progression, lesions without current International Classification of Diseases for Oncology, 3rd Edition codes, and immunodeficiency-associated lymphoproliferative disorders. WHO subtypes are defined in hierarchical groupings, with newly defined groups for small B-cell lymphomas with plasmacytic differentiation and for primary cutaneous T-cell lymphomas. We suggest approaches for applying the hierarchical classification in various epidemiologic settings, including strategies for dealing with multiple coexisting lymphoma subtypes in one patient, and cases with incomplete pathologic information. The pathology materials useful for state-of-the-art epidemiology studies are also discussed. We encourage epidemiologists to adopt the updated InterLymph hierarchical classification, which incorporates the most recent WHO entities while demonstrating their relationship to older classifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“North American registries define multiple primary cancers under the rules of the Surveillance Epidemiology and End Results (SEER) programme.22 Those rules accept more cancers as new primary cancers than the rules of the International Association of Cancer Registries (IACR),23 which are used by most cancer registries in other continents.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationEgner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 6,011
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,950
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,614
Hans, C. P. (2003) · Blood · doi:10.1182/blood-2003-05-1545 · Cited by 4,270
Rosenwald, A., Wright, G. W., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Müller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,832
Self-citationA review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
Research works printed but not linked: 3
- Percy, 2001, Conversion of neoplasms by topography and morphology from the International Classification of Diseases for Oncology, second edition, to International Classification of Diseases for Oncology
- Horner, SEER Cancer Statistics Review, 1975-2006, National Cancer Institute.
- Johnson, 2010, Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual
Cited by
Sorted by citations
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Self-citation2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
Self-citationSmith, A. G., Howell, D. A., Patmore, R. D., Jack, A., & Roman, E. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.450 · Cited by 693
“…more informative descriptive data, including, for example, the application of bridge-coding algorithms to historically coded data (Sant et al, 2010; Turner et al, 2010; Maynadié et al, 2011) and the reporting of specialist hospitalbased case-series frequencies (Yoon et al, 2010; Mozaheb et al,…”
MethodEmerging cancer trends among young adults in the USA: analysis of a population-based cancer registry
Sung, H., Siegel, R. L., Rosenberg, P. S., & Jemal, A. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30267-6 · Cited by 618
Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations
Loh, P.-R., Genovese, G., Handsaker, R. E., Finucane, H. K., Reshef, Y. A., Palamara, P. F., Birmann, B. M., Talkowski, M. E., Bakhoum, S. F., McCarroll, S. A., et al. (2018) · Nature · doi:10.1038/s41586-018-0321-x · Cited by 423
Morton, L. M., Slager, S. L., Cerhan, J. R., WANG, S. S., Vajdic, C. M., Skibola, C. F., Bracci, P. M., de Sanjosé, S., Smedby, K. E. E., Chiu, B. C. ‐., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu013 · Cited by 333
“NHL subtypes were defined according to the World Health Organization (WHO) classification (2,3), and guidelines from the InterLymph Pathology Working Group were used to harmonize NHL subtypes classified using other methods (42,43).”
MethodResultSelf-citationLinet, M. S., Vajdic, C. M., Morton, L. M., de Roos, A. J., Skibola, C. F., Boffetta, P., Cerhan, J. R., Flowers, C. R., de Sanjose, S., Monnereau, A., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu006 · Cited by 241
“Cases were classified according to the WHO classification (31,32) using guidelines from the InterLymph Pathology Working Group (34,35).”
MethodSelf-citationMonogenic and polygenic inheritance become instruments for clonal selection
Loh, P., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 210
“Cancer registry data included date of diagnosis and ICD-O-3 histology and behavior codes, which we used to identify individuals with diagnoses of CLL, MPN, or any blood cancer [45, 46].”
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia
Berndt, S. I., Skibola, C. F., Vijai, J., Camp, N. J., Nieters, A., Wang, Z., Cozen, W., Monnereau, A., Wang, S., Kelly, R. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2652 · Cited by 211
Self-citationSurvival of patients with marginal zone lymphoma
Olszewski, A. J., & Castillo, J. J. (2012) · Cancer · doi:10.1002/cncr.27773 · Cited by 204
“0001 Median follow-up (IQR), mo 42 (17-77) 35 (15-65) 35 (14-66) 47 (20-83) .”
Epidemiology and etiology of diffuse large B-cell lymphoma
WANG, S. S. (2023) · Seminars in Hematology · doi:10.1053/j.seminhematol.2023.11.004 · Cited by 184
Cerhan, J. R., Berndt, S. I., Vijai, J., Ghesquières, H., McKay, J., Wang, S., Wang, Z., Yeager, M., Conde, L., de Bakker, P. I. W., et al. (2014) · Nature Genetics · doi:10.1038/ng.3105 · Cited by 174
Self-citationKhalil, M. O., Morton, L. M., Devesa, S. S., Check, D. P., Curtis, R. E., Weisenburger, D. D., & Dores, G. M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12730 · Cited by 169
Self-citationRisk of lymphoma subtypes after solid organ transplantation in the United States
Clarke, C. A., Morton, L. M., Lynch, C. F., Pfeiffer, R. M., Hall, E. C., Gibson, T. M., Weisenburger, D. D., Martı́nez-Maza, O., Hussain, S. K., Yang, J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.294 · Cited by 151
“We also observed moderately elevated risks (i.e., 2- to 3-fold higher than the general population) for HL, lymphoplasmacytic lymphomas, precursor B- or T-cell lymphoblastic leukaemia/lymphoma, other T-cell lymphomas, and marginal zone lymphoma of MALT type, whereas the risks were not increased for follicular or mantle…”
BackgroundMethodInfluentialSelf-citationCerhan, J. R., Kricker, A., Paltiel, O., Flowers, C. R., WANG, S. S., Monnereau, A., Blair, A. E., Maso, L. D., Kane, E. V., Nieters, A., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu010 · Cited by 132
“Cases were classified according to the World Health Organization classification (23,24) using guidelines from the InterLymph Pathology Working Group (25,26).”
Self-citationEpidemiologic overview of malignant lymphoma
Huh, J. (2012) · The Korean Journal of Hematology · doi:10.5045/kjh.2012.47.2.92 · Cited by 127
“To aid epidemiologic research, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) published the hierarchical classification that enables systematic categorization of the entities into epidemiologically meaningful groups and reclassification of cases that had been coded using…”
MethodEpidemiology and Etiology of Non-Hodgkin Lymphoma
Chiu, B. C. ‐., & Hou, N. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-13150-4_1 · Cited by 117
Self-citationSlager, S. L., Benavente, Y., Blair, A. E., Vermeulen, R. C. H., Cerhan, J. R., Costantini, A. S., Monnereau, A., Nieters, A., Clavel, J., Call, T. G., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu001 · Cited by 113
Self-citationBerndt, S. I., Camp, N. J., Skibola, C. F., Vijai, J., Wang, Z., Gu, J. H., Nieters, A., Kelly, R. S., Smedby, K. E. E., Monnereau, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms10933 · Cited by 118
Self-citationSkibola, C. F., Berndt, S. I., Vijai, J., Conde, L., Wang, Z., Yeager, M., de Bakker, P. I. W., Birmann, B. M., Vajdic, C. M., Foo, J. N., et al. (2014) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.09.004 · Cited by 111
Self-citationNew insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy
Chihara, D., Nastoupil, L. J., Williams, J. N., Lee, P. Y. K., Koff, J. L., & Flowers, C. R. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1023712 · Cited by 105
Epidemiology of haematological malignancies in people living with HIV
Kimani, S., Painschab, M., Horner, M., Muchengeti, M. M., Fedoriw, Y. D., Shiels, M. S., & Gopal, S. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30118-1 · Cited by 103
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
Costa, L. J., Xavier, A. C., Wahlquist, A. E., & Hill, E. G. (2013) · Blood · doi:10.1182/blood-2012-12-475558 · Cited by 95
“The latter is particularly relevant in the context of multiple reclassifications of hematological neoplasms that occurred during the time span covered by the study.(21) For instance, some B-cell lymphomas harboring c-myc translocation (and potentially classified as BL in the past) are now classified as diffuse large B…”
BackgroundLymphoid malignancies in US Asians: incidence rate differences by birthplace and acculturation
Clarke, C., Glaser, S., Gomez, S., Wang, S. S., Keegan, T., Yang, J., & Chang, E. (2011) · Cancer Epidemiology, Biomarkers and Prevention · doi:10.1158/1055-9965.epi-11-0038 · Cited by 91
“By using InterLymph Consortium guidelines (9, 10), we further classified lymphoid malignancies by histologic subtype into diffuse large B-cell lymphoma (DLBCL; ICD-O-3 morphology codes 9680 and 9684, excluding those with code 9684 and a T-cell, NK-cell, or null-cell immunophenotype); follicular lymphoma (FL; codes 969…”
Self-citationZocchi, M. R., Catellani, S., Canevali, P., Tavella, S., Garuti, A., Villaggio, B., Zunino, A., Gobbi, M., Orcioni, G. F., Kunkl, A., et al. (2011) · Blood · doi:10.1182/blood-2011-07-370841 · Cited by 90
Bracci, P. M., Benavente, Y., Turner, J., Paltiel, O., Slager, S. L., Vajdic, C. M., Norman, A. D., Cerhan, J. R., Chiu, B. C. ‐., Becker, N., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu011 · Cited by 85
“Our use of the InterLymph NHL classification (14,15), combined with site information, helped to diminish additional mis-”
MethodSelf-citationCollaborators, F. T. M. W. S., Kroll, M. E., Murphy, F., Pirie, K. L., REEVES, G. K., Green, J., & Beral, V. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.333 · Cited by 84
“A hierarchical classification based on ICDO-3 has been used in recent international collaborative studies (Morton et al, 2007; Sant et al, 2010; Turner et al, 2010).”
MethodLymphoid neoplasm incidence by WHO subtype in Australia 1982–2006
van Leeuwen, M. T., Turner, J., Joske, D. J. L., Falster, M. O., Srasuebkul, P., Meagher, N. S., Grulich, A. E., Giles, G. G., & Vajdic, C. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.28849 · Cited by 80
“The WHO Classification represents consensus classification for clinical, pathologic and scientific use and wholly incorporates the International Classification of Diseases for Oncology, Third Edition (ICD-O-3, 2001).(6,11) Herein we use population-based cancer registry data to systematically describe subtype-specific…”
BackgroundMethodInfluentialSelf-citationMarcos‐Gragera, R., Allemani, C., Ţereanu, C., Angelis, R. D., Capocaccia, R., Maynadié, M., Luminari, S., Ferretti, S., Johannesen, T. B., Sankila, R. J., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.034264 · Cited by 74
“The HAEMACARE lymphoid neoplasm grouping system incorporates the changes introduced by the 2001 and 2008 WHO classifications(1,8) and is consistent with the classification of lymphoid neoplasms for epidemiological research proposed by the Pathology Working Group of the International Lymphoma Epidemiology Consortium (I…”
MethodSelf-citationChang, E. T., Canchola, A. J., Cockburn, M., Lu, Y., WANG, S. S., Bernstein, L., Clarke, C. A., & Horn‐Ross, P. L. (2011) · Blood · doi:10.1182/blood-2011-02-336065 · Cited by 71
“Yes, first at ages 16-20 y 21 274 (18) Yes, first at age 21 y 11 059 (9) Yes, missing age 831 (1) Yes, 1-2 times 33 628 (28) Yes, 3-4 times 22 312 (18) Yes, 5 times 21 675 (18) Yes, missing number of times 2314 (2) Missing 1945 (2) History of melanoma or other skin cancer No 108 432 (89) Yes 12 784 (11) Minimum baseli…”
Self-citationCollaborators, O. B. O. T. M. W. S., Murphy, F., Kroll, M. E., Pirie, K. L., REEVES, G. K., Green, J., & Beral, V. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.159 · Cited by 71
Monnereau, A., Troussard, X., Belot, A., Guizard, A., Woronoff, A., Bara, S., Lapôtre‐Ledoux, B., Iwaz, J., Trétarre, B., Maynadié, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27889 · Cited by 70
Self-citationCheckoway, H., Boffetta, P., Mundt, D. J., & Mundt, K. A. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0055-2 · Cited by 69
“The InterLymph Consortium of lymphoma epidemiology has made an effort to adapt the last two versions of the WHO classification to epidemiologic studies, following a hierarchical approach [33, 34].”
MethodWANG, S. S., Vajdic, C. M., Linet, M. S., Slager, S. L., Voutsinas, J. M., Nieters, A., de Sanjosé, S., Cozen, W., Alarcón, G. S., Martı́nez-Maza, O., et al. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwu290 · Cited by 67
Self-citationInsurance status is related to diffuse large B‐cell lymphoma survival
Han, X., Jemal, A., Flowers, C. R., Sineshaw, H. M., Nastoupil, L. J., & Ward, E. (2014) · Cancer · doi:10.1002/cncr.28549 · Cited by 65
Angelis, R. D., Minicozzi, P., Sant, M., Maso, L. D., Brewster, D. H., Osca‐Gelis, G., Visser, O. J., Maynadié, M., Marcos‐Gragera, R., Troussard, X., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.003 · Cited by 65
Self-citationA genome-wide association study of marginal zone lymphoma shows association to the HLA region
Vijai, J., Wang, Z., Berndt, S. I., Skibola, C. F., Slager, S. L., de Sanjosé, S., Melbye, M., Glimelius, B., Bracci, P. M., Conde, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms6751 · Cited by 65
Self-citationWANG, S. S., Flowers, C. R., Kadin, M. E., Chang, E. T., Hughes, A. M., Ansell, S. M., Feldman, A. L., Lightfoot, T., Boffetta, P., Melbye, M., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu012 · Cited by 65
“Cases were classified according to the World Health Organization classification (3,19) using guidelines from the InterLymph Pathology Working Group (20,21).”
BackgroundMethodSelf-citationPosttransplantation Lymphoproliferative Disease: Proposed Imaging Classification
Camacho, J. C., Moreno, C. C., Harri, P. A., Aguirre, D. A., Torres, W. E., & Mittal, P. (2014) · Radiographics · doi:10.1148/rg.347130130 · Cited by 63
Morton, L. M., Sampson, J. N., Cerhan, J. R., Turner, J., Vajdic, C. M., WANG, S. S., Smedby, K. E. E., de Sanjosé, S., Monnereau, A., Benavente, Y., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu005 · Cited by 62
“† We grouped cases into NHL subtypes according to the WHO classification (2,3) using guidelines from the InterLymph Pathology Working Group (64,65).”
MethodResultInfluentialSelf-citationMachiela, M. J., Lan, Q., Slager, S. L., Vermeulen, R. C. H., Teras, L. R., Camp, N. J., Cerhan, J. R., Spinelli, J. J., Wang, S. S., Nieters, A., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw027 · Cited by 58
“NHL diagnoseswere verified bymedical and pathology reports to meet InterLymph and World Health Organization (WHO) criteria (32,33).”
MethodSelf-citationTeras, L. R., Diver, W. R., Deubler, E. L., Krewski, D. R., Flowers, C. R., Switchenko, J. M., & Gapstur, S. M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32202 · Cited by 58
“Hematologic cancer subtypes were defined using the 2008 World Health Organization classification scheme6 adapted for epidemiologic studies by the International Lymphoma Epidemiology Consortium Pathology Working Group.7 Histology codes from the International Classification of Diseases for Oncology, second and third edi…”
Examining racial differences in diffuse large B-cell lymphoma presentation and survival
Flowers, C. R., Shenoy, P. J., Borate, U., Bumpers, K., Douglas-Holland, T., King, N., Brawley, O. W., Lipscomb, J., Lechowicz, M. J., Sinha, R., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.708751 · Cited by 57
“[27] We also acknowledge that the World Health Organization (WHO) classification of lymphomas changed over the time period of the study and other classifications were previously used; all cases were identified and selected using the 2008 WHO system.[11,28,29] Missing data in the earlier years of analysis precluded us…”
MethodContributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends
Howlader, N., Morton, L. M., Feuer, E. J., Besson, C., & Engels, E. A. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0921 · Cited by 57
“We identified cases ofDLBCL,CLL/SLL, FL, andPTCLusing histology codes (29).”
Self-citationDonzel, M., Bonjour, M., Combes, J., Broussais, F., Sesques, P., Traverse‐Glehen, A., & de Martel, C. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101674 · Cited by 56
Aschebrook‐Kilfoy, B., Cocco, P., Vecchia, C. L., Chang, E. T., Vajdic, C. M., Kadin, M. E., Spinelli, J. J., Morton, L. M., Kane, E. V., Sampson, J. N., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu008 · Cited by 56
“Cases were classified according to the World Health Organization classification (5,21) using guidelines from the InterLymph Pathology Working Group (22,23).”
MethodSelf-citationIncidence of haematological malignancies by ethnic group in E ngland, 2001–7
Shirley, M. H., Sayeed, S., Barnes, I. M., Finlayson, A. E. T., & Ali, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12562 · Cited by 51
Marseillevirus in lymphoma: a giant in the lymph node
Aherfi, S., Colson, P., Audoly, G., Nappez, C., Xerri, L., Valensi, A., Million, M., Lépidi, H., Costello, R. T., & Raoult, D. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30051-2 · Cited by 50
Dicamba use and cancer incidence in the agricultural health study: an updated analysis
Lerro, C. C., Hofmann, J. N., Andreotti, G., Koutros, S., Parks, C. G., Blair, A. E., Albert, P. S., Lubin, J. H., Sandler, D. P., & Freeman, L. E. B. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyaa066 · Cited by 50
Germain, C., Guillaudeux, T., Galsgaard, E. D., Hervouet, C., Tekaya, N., Gallouët, A.-S., Fassy, J., Bihl, F., Poupon, G., Lazzari, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026503 · Cited by 48
Conroy, S. M., Maskarinec, G., Morimoto, Y., Franke, A. A., Cooney, R. V., Wilkens, L. R., Goodman, M. T., Hernadez, B. Y., Marchand, L. L., Henderson, B. E., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0947 · Cited by 49
“3 Introduction Non-Hodgkin lymphoma (NHL) is an etiologically, clinically, and histologically heterogeneous group of malignant diseases of the lymphocytes (1).”
InfluentialCancer incidence in France over the 1980–2012 period: Hematological malignancies
Guyader-Peyrou, S. L., Belot, A., Maynadié, M., Binder-Foucard, F., Remontet, L., Troussard, X., Bossard, N., & Monnereau, A. (2016) · Revue d Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2015.12.017 · Cited by 49
Self-citationNabhan, C., Aschebrook‐Kilfoy, B., Chiu, B. C. ‐., Kruczek, K. R., Smith, S. M., & Evens, A. M. (2014) · American Journal of Hematology · doi:10.1002/ajh.23708 · Cited by 48
Self-citationSmedby, K. E. E., Sampson, J. N., Turner, J., Slager, S. L., Maynadié, M., Roman, E., Habermann, T. M., Flowers, C. R., Berndt, S. I., Bracci, P. M., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu007 · Cited by 48
“Cases were classified according to the WHO classification (3,4) using guidelines from the InterLymph Pathology Working Group (22,23).”
MethodSelf-citationNabhan, C., Aschebrook‐Kilfoy, B., Chiu, B. C. ‐., Smith, S. M., Shanafelt, T. D., Evens, A. M., & Kay, N. E. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.898758 · Cited by 45
Self-citationKoeman, T., van den Brandt, P. A., Slottje, P., Schouten, L. J., Goldbohm, R. A., Kromhout, H., & Vermeulen, R. C. H. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0322-x · Cited by 45
“A complicating factor in interpreting the existing literature is that the classification of lymphoma has undergone many changes over the years [40].”
Backgroundvan Leeuwen, M. T., Turner, J., Falster, M. O., Meagher, N. S., Joske, D. J. L., Grulich, A. E., Giles, G. G., & Vajdic, C. M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28081 · Cited by 43
Self-citationPhysical Activity in Relation to Risk of Hematologic Cancers: A Systematic Review and Meta-analysis
Jochem, C., Leitzmann, M. F., Keimling, M., Schmid, D., & Behrens, G. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0699 · Cited by 43
“Some studies did not specify the classification scheme used, whereas other studies provided detailed information about the use of common classification schemes such as the second or third editions of the International Classification of Diseases for Oncology (ICD-O-2/-3) or the InterLymph classification scheme (64).”
Using primary site as a predictor of survival in mantle cell lymphoma
Ambinder, A. J., Shenoy, P. J., Nastoupil, L. J., & Flowers, C. R. (2013) · Cancer · doi:10.1002/cncr.27898 · Cited by 42
“We identified MCL cases using ICD-O-3 histology code 9673(24) in accordance with the InterLymph Consortium classification of lymphoid neoplasms for epidemiologic research based on the 2008WHO classification.(25,26)”
Methodvan Veldhoven, K., Khan, A. E., Teucher, B., Rohrmann, S., Raaschou‐Nielsen, O., Tjønneland, A. M., Overvad, K., Vigl, M., Boeing, H., Benetou, V., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.010 · Cited by 43
Bailey, C., Richardson, L. C., Allemani, C., Bonaventure, A., Harewood, R., Moore, A. R., Stewart, S. L., Weir, H. K., Coleman, M. P., & CONCORD Working Group (US members) (2018) · Cancer · doi:10.1002/cncr.31674 · Cited by 43
Monnereau, A., Slager, S. L., Hughes, A. M., Smith, J. A., Glimelius, B., Habermann, T. M., Berndt, S. I., Staines, A. S., Norman, A. D., Cerhan, J. R., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu004 · Cited by 41
Self-citationContributions of HIV to Non-Hodgkin Lymphoma Mortality Trends in the United States
Howlader, N., Shiels, M. S., Mariotto, A. B., & Engels, E. A. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0273 · Cited by 41
“We selectedNHL cases based on the SEER variable "Lymphoma Subtype Recode ICD-O-3/WHO 2008" (13, 14).”
MethodVajdic, C. M., Landgren, O., McMaster, M. L., Slager, S. L., Brooks-Wilson, A. R., Smith, A., Staines, A. S., Doǧan, A., Ansell, S. M., Sampson, J. N., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu002 · Cited by 40
“All LPL/WM cases met the criteria for LPL/WM described by the World Health Organization classification (1,32) and satisfied the classification suggested subsequently by the InterLymph Pathology Working Group (33,34).”
MethodSelf-citationTeras, L. R., Diver, W. R., Turner, M. C., Krewski, D. R., Sahar, L., Ward, E., & Gapstur, S. M. (2016) · Environmental Research · doi:10.1016/j.envres.2016.03.002 · Cited by 40
A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk
Campa, D., Butterbach, K., Slager, S. L., Skibola, C. F., de Sanjosé, S., Benavente, Y., Becker, N., Foretová, L., Maynadié, M., Cocco, P., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26436 · Cited by 40
Self-citationNieters, A., Conde, L., Slager, S. L., Brooks-Wilson, A. R., Morton, L. M., Skibola, D. R., Novak, A. J., Riby, J. E., Ansell, S. M., Halperin, E., et al. (2012) · Blood · doi:10.1182/blood-2012-05-427989 · Cited by 41
Self-citationMbulaiteye, S. M., Morton, L. M., Sampson, J. N., Chang, E. T., Costas, L., de Sanjosé, S., Lightfoot, T. J., Kelly, J. L., Friedberg, J. W., Cozen, W., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu003 · Cited by 39
“An interdisciplinary team of pathologists and epidemiologists reviewed the pathology reports from the original studies to ensure that the NHL subtype classification was as accurate and specific as possible using guidelines from the InterLymph Pathology Working Group (19,20).”
MethodSelf-citationErrahhali, M. E., Errahhali, M. E., Boulouiz, R., Ouarzane, M., & Bellaoui, M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2205-5 · Cited by 39
“This 4th edition of the WHO classification has refined the 2001 classification on the basis of new and cumulative experimental evidence [2, 5–11].”
BackgroundPeriodontal disease and risk of non‐Hodgkin lymphoma in the Health Professionals Follow‐Up Study
Bertrand, K. A., Shingala, J., Evens, A. M., Birmann, B. M., Giovannucci, E. L., & Michaud, D. S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30518 · Cited by 39
Castillo, J. J., Olszewski, A. J., Hunter, Z. R., Kanan, S., Meid, K., & Treon, S. P. (2015) · Cancer · doi:10.1002/cncr.29334 · Cited by 38
“WM cases were defined according to the InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research, which is based on codes 9671/3 (lymphoplasmacytic lymphoma [LPL]) and 9761/3 (WM) from the 2008 World Health Organization (WHO) International Classification of Diseases for Oncology, Version…”
MethodA case–control study of HIV infection and cancer in the era of antiretroviral therapy in R wanda
Mpunga, T., Znaor, A., Uwizeye, F. R., Uwase, A., Munyanshongore, C., Franceschi, S., & Clifford, G. M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31537 · Cited by 38
“In addition, lymphomas were classified into subtypes according to the 2010 update of the InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research.(12) Last (except for lymphoma subtype analyses), rare cancer types (<4 cases) were grouped into a miscellaneous category (n5 55) and combined…”
MethodSchonfeld, S. J., Morton, L. M., de González, A. B., Curtis, R. E., & Kitahara, C. M. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101664 · Cited by 38
“First primary malignancies were classified using the International Classification of Diseases for Oncology (ICD-O-3) morphology and site codes [17] and the World Health Organization (WHO) classification of lymphoid neoplasms [18].”
MethodSelf-citationOlszewski, A. J., & Ali, S. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1900-4 · Cited by 37
Bassig, B. A., Friesen, M. C., Vermeulen, R. C. H., Shu, X., Purdue, M. P., Stewart, P. A., Xiang, Y.-B., Chow, W., Zheng, T., Ji, B., et al. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1408307 · Cited by 36
“…of each of the exposure tertiles. notable that most previous cohorts have not included lymphoid leukemia cases in their NHL case definition, whereas we included cases of both CLL/small lymphocytic lymphoma and ALL, which are grouped with NHL in the most recent classifications (Turner et al. 2010).”
Self-citationWANG, S. S., Carrington, M. N., Berndt, S. I., Slager, S. L., Bracci, P. M., Voutsinas, J. M., Cerhan, J. R., Smedby, K. E. E., Hjalgrim, H., Vijai, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2900 · Cited by 36
Self-citationCahoon, E. K., Pfeiffer, R. M., Wheeler, D. C., Arhancet, J. P., Lin, S., Alexander, B. H., Linet, M. S., & Freedman, D. M. (2014) · International Journal of Cancer · doi:10.1002/ijc.29237 · Cited by 35
“NHL cases were grouped into lymphoid neoplasm subtypes as defined by the InterLymph hierarchical classification for epidemiologic research.(29)”
MethodSelf-citationDaniel, C. R., Sinha, R. R., Park, Y., Graubard, B. I., Hollenbeck, A. R., Morton, L. M., & Cross, A. J. (2012) · Journal of Nutrition · doi:10.3945/jn.112.158113 · Cited by 35
“Using the International Classification of Diseases for Oncology, 3rd edition (ICD-0–3) (25), in accordance with the WHO classification and the International Lymphoma Epidemiology Consortium (InterLymph) guidelines (26), we restricted our definition of primary incident NHL to the following histology codes: 9591, 9670–7…”
MethodSelf-citationOlszewski, A. J., & Desai, A. J. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.225 · Cited by 35
Hauswald, H., Zwicker, F., Rochet, N., Uhl, M., Hensley, F. W., Debus, J., Herfarth, K. K., & Bischof, M. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-118 · Cited by 34
Exploring Risk Factors for Follicular Lymphoma
Ambinder, A. J., Shenoy, P. J., Malik, N., Maggioncalda, A., Nastoupil, L. J., & Flowers, C. R. (2012) · Advances in Hematology · doi:10.1155/2012/626035 · Cited by 34
“In 2007, the International Lymphoma Epidemiology Consortium (InterLymph) devised a hierarchical classification scheme that incorporated elements of the 2001 World Health Organization (WHO) Classification of Lymphoid Neoplasms and the International Classification of Diseases for Oncology (ICD-O, third edition), as well…”
MethodZimmermann, M., Oehler, C., Mey, U., Ghadjar, P., & Zwahlen, D. R. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0690-y · Cited by 34
“Omitting RT in the treatment of NHLs should not be considered outside of well conducted prospective studies.”
BackgroundInfluentialLeo, Q. J. N., Ollberding, N. J., Wilkens, L. R., Kolonel, L. N., Henderson, B. E., Marchand, L. L., & Maskarinec, G. (2014) · Cancer Causes & Control · doi:10.1007/s10552-014-0447-6 · Cited by 32
“NHL types were classified into the following categories according to the adaptation of the World Health Organization classification for epidemiologic studies using the International Classification of Disease Oncology version 3 [21, 22]: DLBCL (9679, 9680, 9684), FL (9690, 9691, 9695, 9698), chronic lymphocytic leukemi…”
MethodBerndt, S. I., Vijai, J., Benavente, Y., Camp, N. J., Nieters, A., Wang, Z., Smedby, K. E. E., Kleinstern, G., Hjalgrim, H., Besson, C., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01711-0 · Cited by 33
“NHL subtype was harmonized centrally at the InterLymph Data Coordinating Center according to the hierarchical classification proposed by the InterLymph Pathology Working Group based on the World Health Organization (WHO) classification (2008) [33].”
MethodSelf-citationSchinasi, L. H., Roos, A. J. D., Ray, R. M., Edlefsen, K. L., Parks, C. G., Howard, B. V., Meliker, J. R., Bonner, M. R., Wallace, R. B., & LaCroix, A. Z. (2015) · Annals of Epidemiology · doi:10.1016/j.annepidem.2015.08.002 · Cited by 32
“LH neoplasms were categorized into World Health Organisation subtypes [24] according to InterLymph Consortium recommendations [25].”
MethodDisparities in survival by insurance status in follicular lymphoma
Goldstein, J., Nastoupil, L. J., Han, X., Jemal, A., Ward, E., & Flowers, C. R. (2018) · Blood · doi:10.1182/blood-2018-03-839035 · Cited by 32
Teras, L. R., Patel, A. V., Hildebrand, J. S., & Gapstur, S. M. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.722216 · Cited by 32
Casulo, C., Day, B., Dawson, K. L., Zhou, X., Flowers, C. R., Farber, C. M., Hainsworth, J. D., Cerhan, J. R., Link, B. K., Zelenetz, A. D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv375 · Cited by 30
“Follicular lymphoma (FL) represents the most common indolent non-Hodgkin lymphoma (NHL) in the USA and Europe, accounting for an estimated 20% of all NHL cases [1].”
Self-citationIwanaga, M., Chiang, C., Soda, M., Lai, M., Yang, Y., Miyazaki, Y., Matsuo, K., Matsuda, T., & Sobue, T. (2013) · International Journal of Cancer · doi:10.1002/ijc.28343 · Cited by 30
Musso, A., Catellani, S., Canevali, P., Tavella, S., Venè, R., Boero, S., Pierri, I., Gobbi, M., Kunkl, A., Ravetti, J., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.097311 · Cited by 30
“LNMSC inhibit NKG2D-mediated lymphoid cell killing but not ADCC Data from 48 NHL patients (30 FL, 18 DLCL), who had been classified according to the WHO classification, were analyzed (Online Supplementary Table S1).(32) Co-culture of Vd2 T lymphocytes with LNMSC (Online Supplementary Appendix and Online Supplementary…”
MethodKim, C., Bassig, B. A., Seow, W. J., Hu, W., Purdue, M. P., Huang, W., Liu, C., Cheng, W.-L., Männistö, S., Vermeulen, R. C. H., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0753 · Cited by 29
“We utilized the latest revision of the INTERLYMPH working group definitions for histologic subtype classifications ofNHL (23), which allowed formore specific analyses of lymphoma subtypes.”
MethodInfluentialReproductive factors and non-Hodgkin lymphoma: A systematic review
Costas, L., de Sanjosé, S., & Infante‐Rivard, C. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.07.004 · Cited by 28
Na, R., Laaksonen, M. A., Grulich, A. E., Meagher, N. S., McCaughan, G. W., KEOGH, A. M., & Vajdic, C. M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14083 · Cited by 30
“We identified NHL diagnoses on the basis of International Classification of Diseases for Oncology (ICD-O) codes (Turner et al, 2010).”
MethodSelf-citationTeras, L. R., Gapstur, S. M., Diver, W. R., Birmann, B. M., & Patel, A. V. (2012) · International Journal of Cancer · doi:10.1002/ijc.27445 · Cited by 28
Engels, E. A., Parsons, R., Besson, C., Morton, L. M., Enewold, L., Ricker, W., Yanik, E. L., Arem, H. E., Austin, A. A., & Pfeiffer, R. M. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0212 · Cited by 28
“We included the five most common NHL subtypes, defined according to the World Health Organization classification (17): CLL/SLL, DLBCL, follicular lymphoma, MZL, and TCLs considered as a group.”
MethodSelf-citationCastillo, J. J., Olszewski, A. J., Kanan, S., Meid, K., Hunter, Z. R., & Treon, S. P. (2015) · American Journal of Hematology · doi:10.1002/ajh.24052 · Cited by 27
“WM/LPL was defined according to the InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research, based on the ICD-O-3 codes 9671/3 (LPL) and 9761/3 (WM) [10].”
MethodCommon infection-related conditions and risk of lymphoid malignancies in older individuals
Anderson, L. A., Atman, A., McShane, C. M., Titmarsh, G. J., Engels, E. A., & Koshiol, J. E. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.173 · Cited by 26
“Common infection-related conditions and risk of lymphoid malignancies in older individuals”
BackgroundMethodRoos, A. J. D., Schinasi, L. H., Miligi, L., Cerhan, J. R., Bhatti, P., Mannetje, A. ’., Baris, D., Benavente, Y., Benke, G., Clavel, J., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33740 · Cited by 25
“Data from case-control studies participating in InterLymph were pooled for this investigation of occupational insecticide exposures in relation to risk of non-Hodgkin lymphoid malignancies (NHL), including the major NHL subtypes diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), as well as chronic lym…”
MethodSelf-citationEtiology of non-Hodgkin lymphoma: A review from epidemiologic studies
Luo, J., Craver, A., Bahl, K., Stepniak, L., Moore, K., King, J., Zhang, Y., & Aschebrook‐Kilfoy, B. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.08.003 · Cited by 25
Herbicide use in farming and other jobs in relation to non-Hodgkin’s lymphoma (NHL) risk
Roos, A. J. D., Fritschi, L., Ward, M. H., Monnereau, A., Hofmann, J. N., Bernstein, L., Bhatti, P., Benavente, Y., Benke, G., Casabonne, D., et al. (2022) · Occupational and Environmental Medicine · doi:10.1136/oemed-2022-108371 · Cited by 25
Self-citation
Metadata
- Authors
- Turner, J. J., Morton, L. M., Linet, M. S., Clarke, C. A., Kadin, M. E., Vajdic, C. M., Monnereau, A., Maynadié, M., Chiu, B. C.-H., Marcos-Gragera, R., Costantini, A. S., Cerhan, J. R., & Weisenburger, D. D.
- Affiliations
- Douglass Hanly Moir Pathology (AU)
- National Institutes of Health (US)
- Cancer Prevention Institute of California (US)
- Boston University (US)
- UNSW Sydney (AU)
- Inserm (FR)
- Université de Bourgogne (FR)
- University of Chicago (US)
- Epidemiology Unit, Cancer Registry of Girona, Oncology Planning, Department of Health, Institute of Biomedical Investigation, Girona, Spain;
- Cancer Research and Prevention Institute Epidemiology, Florence, Italy;
- Mayo Clinic (US)
- University of Nebraska Medical Center (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-11-18
- Volume
- 116
- Issue
- 20
- Pages
- e90-e98
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2993636
- OpenAlex
- W2070728536
- Cited by
- 231
- References
- 45
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 5 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 19 · 2019: 11 · 2018: 15 · 2017: 7 · 2016: 18 · 2015: 25 · 2014: 39 · 2013: 25 · 2012: 16
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- National Institutes of Health (CA97274)
- National Cancer Institute (CA97274, R01 CA97274, R01CA092153, P50CA097274)
- National Center for Research Resources (P20RR018757)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Hematology › Hematological disorders and diagnostics
- Keywords
- lymphoid malignancies, hierarchical classification, lymphoma epidemiology, lymphoma subtypes, primary cutaneous T-cell lymphoma
- MeSH terms
- Humans, Lymphoma, Societies, Medical, World Health Organization, Epidemiologic Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
